Leukaemia

BMT-CTN1506 (“MORPHO”) was an international phase III trial investigating the use of post-haematopoietic cell transplantation maintenance with the FLT3 inhibitor, gilteritinib, in patients with FLT3-ITD acute myeloid leukaemia. The aims and findings of the trial, as well as questions that remain to be answered, are discussed in this touchHAEMATOLOGY interview with Dr Mark Levis (Sidney […]

We caught up with Prof Jorge Cortes (Georgia Cancer Center, Augusta University, GA, USA) to discuss his highlights from the recent EHA 2023 Congress, including two clinical trials that investigated the use of quizarpenib in patients with acute myeloid leukaemia. Abstracts discussed: Abstract S130: ‘Preliminary Results of QUIWI: A Double Blinded, Randomized Clinical Trial Comparing […]

Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukaemia (ALL) has been associated with poor outcomes, and allogeneic hematopoietic cell transplantation (allo-HCT) is the current recommended treatment. Professor Robin Foà (Sapienza University of Rome, Italy) joins us after the EBMT23 meeting to discuss his perspective on the ongoing debate of whether we should transplant all patients with Philadelphia Ph+ […]

“We are facing an exciting era of fast-paced drug development in acute myeloid leukaemia” writes Gianfranco Bittar and colleagues at Baylor College of Medicine, Houston, TX, USA, in a review published in touchREVIEWS in Oncology & Haematology. In 2020, there were an estimated 21,450 new patients with acute myeloid leukaemia (AML) and 11,180 AML-related deaths […]

Histone-lysine N-methyltransferase 2A rearrangements (KMT2Ar) and mutant nucleophosmin 1 (mNPM1) occur in approximately 5–10% and 30% of patients with acute myeloid leukaemia (AML), respectively.1,2 Both mutations are associated with the founding events in the development of leukaemia.1 In particular, KMT2Ar functions in a protein complex requiring menin, leading to the deregulation of genes, including homeobox A cluster […]

Frontline treatment with azacitidine plus venetoclax (AZA/VEN) significantly improved remission rates and survival duration for older, frail and high-risk patients with acute myeloid leukaemia (AML) in the pivotal VIALE-A trial.1 The combination is approved for use in this setting,2 but longer-term survival remains suboptimal.3 At ASH 2022 in New Orleans, Louisiana, several studies aimed to […]

Prof Barbara Eichhorst (University Hospital Cologne, Cologne, Germany) discusses the Phase 3 GAIA/CLL13 TRIAL trial investigating venetoclax and obinutuzumab in the treatment of fit patients with CLL. The abstract ‘TIME-LIMITED VENETOCLAX-OBINUTUZUMAB +/- IBRUTINIB IS SUPERIOR TO CHEMOIMMUNOTHERAPY IN FRONTLINE CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): PFS CO-PRIMARY ENDPOINT OF THE RANDOMIZED PHASE 3 GAIA/CLL13 TRIAL’ (Abstract: LB2365) […]